- Home
- NKTX vs BMEA Comparison
NKTX vs BMEA Comparison
Compare NKTX & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTX
- BMEA
- Stock Information
- Founded
- NKTX 2015
- BMEA 2017
- Country
- NKTX United States
- BMEA United States
- Employees
- NKTX N/A
- BMEA N/A
- Industry
- NKTX Biotechnology: Pharmaceutical Preparations
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- NKTX Health Care
- BMEA Health Care
- Exchange
- NKTX Nasdaq
- BMEA Nasdaq
- Market Cap
- NKTX 170.8M
- BMEA 145.0M
- IPO Year
- NKTX 2020
- BMEA 2021
- Fundamental
- Price
- NKTX $2.47
- BMEA $3.98
- Analyst Decision
- NKTX Strong Buy
- BMEA Buy
- Analyst Count
- NKTX 5
- BMEA 13
- Target Price
- NKTX $15.20
- BMEA $27.92
- AVG Volume (30 Days)
- NKTX 1.5M
- BMEA 939.5K
- Earning Date
- NKTX 11-07-2024
- BMEA 10-29-2024
- Dividend Yield
- NKTX N/A
- BMEA N/A
- EPS Growth
- NKTX N/A
- BMEA N/A
- EPS
- NKTX N/A
- BMEA N/A
- Revenue
- NKTX N/A
- BMEA N/A
- Revenue This Year
- NKTX N/A
- BMEA N/A
- Revenue Next Year
- NKTX N/A
- BMEA N/A
- P/E Ratio
- NKTX N/A
- BMEA N/A
- Revenue Growth
- NKTX N/A
- BMEA N/A
- 52 Week Low
- NKTX $2.08
- BMEA $3.61
- 52 Week High
- NKTX $16.24
- BMEA $20.21
- Technical
- Relative Strength Index (RSI)
- NKTX 50.49
- BMEA 35.19
- Support Level
- NKTX $2.19
- BMEA $3.78
- Resistance Level
- NKTX $2.70
- BMEA $4.29
- Average True Range (ATR)
- NKTX 0.15
- BMEA 0.29
- MACD
- NKTX 0.03
- BMEA 0.14
- Stochastic Oscillator
- NKTX 54.90
- BMEA 49.26
About NKTX Nkarta Inc.
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.